(76) demonstrated that IDO1 inhibition downregulates MDM2 expression in DLBCL cells, activates the p53 signaling pathway, and induces cell cycle arrest and apoptosis, ultimately improving patient outcomes. Here, MDM2 is linked to diffuse large B-cell lymphoma.